Nicholasville

Researchers are evaluating the safety and effectiveness of a drug called Imeroprubart in adults who have Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a condition affecting the nerves. This Phase 2b study is conducted at multiple centers and uses a randomized, double-blind, placebo-controlled design to compare Imeroprubart with a placebo in participants with active CIDP. Participants receive either Imeroprubart or a matching placebo by subcutaneous injection once a week. The treatment is given for 24 weeks during the first period, followed by an extension period of 52 weeks for continued monitoring. Imeroprubart is dosed once weekly by injection under the skin, and the placebo group receives matching injections during the initial 24 weeks. Throughout the study, participants undergo various assessments to monitor their health and response to treatment. Researchers measure the proportion of participants who remain free from disease relapse by Week 24. Safety and efficacy are closely tracked with clinical evaluations and diagnostic tests. The total duration of participation includes the treatment periods and follow-up to observe outcomes and potential side effects.

Researchers are evaluating the efficacy, safety, and tolerability of IMVT-1402 in adults diagnosed with mild to severe generalized myasthenia gravis. This Phase 3 study focuses on participants classified as Class II, III, or IVa by the Myasthenia Gravis Foundation of America and who have a certain level of daily living impairment due to their condition. Participants will receive either IMVT-1402 or a placebo through weekly subcutaneous injections. The study includes multiple treatment periods: an initial 12-week period where participants receive either Dose 1 or Dose 2 of IMVT-1402 or placebo, followed by additional periods where IMVT-1402 is administered weekly for up to 14 weeks and then 52 weeks, depending on the dose group. Throughout the study, participants will be regularly assessed for changes in their MG activities of daily living score from baseline through week 12. Safety and tolerability will also be monitored during and after treatment. Participants must be able to comply with study procedures and provide informed consent, with a total participation age range of 18 to 80 years.